New hope for sickle cell patients: drug aims to cut painful crises

NCT ID NCT06439082

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests a drug called crizanlizumab in people aged 12 and older with sickle cell disease who have frequent pain crises. The goal is to see if the drug can reduce the number of these crises compared to a placebo. Participants may also continue taking their usual treatments like hydroxyurea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder sickle cell disease Sickle Cell Trait Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

Augusta University Georgia
RECRUITING

Augusta, Georgia, 30912, United States
Childrens Hospital at Montefiore
RECRUITING

The Bronx, New York, 10467, United States
Childrens National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Ctr for Inherited Blood Disorders
RECRUITING

Orange, California, 92868, United States
East Carolina University
RECRUITING

Greenville, North Carolina, 27834, United States
Norton Children s Hospital
RECRUITING

Louisville, Kentucky, 40202, United States
Novartis Investigative Site
RECRUITING

Salvador, Estado de Bahia, 41253-190, Brazil
Novartis Investigative Site
RECRUITING

São Luís, Maranhão, 65020-070, Brazil
Novartis Investigative Site
RECRUITING

Campinas, São Paulo, 13083-970, Brazil
Novartis Investigative Site
RECRUITING

Ribeirão Preto, São Paulo, 14048-900, Brazil
Novartis Investigative Site
RECRUITING

Sao Jose Rio Preto, São Paulo, 15090 000, Brazil
Novartis Investigative Site
RECRUITING

São Paulo, São Paulo, 01232-010, Brazil
Novartis Investigative Site
RECRUITING

São Paulo, São Paulo, 08270-070, Brazil
Novartis Investigative Site
RECRUITING

Medellín, Antioquia, 050001, Colombia
Novartis Investigative Site
RECRUITING

Cali, Valle del Cauca Department, 760032, Colombia
Novartis Investigative Site
RECRUITING

Cali, Valle del Cauca Department, 760046, Colombia
Novartis Investigative Site
RECRUITING

Montería, 230001, Colombia
Novartis Investigative Site
RECRUITING

Ahero, Kisumu County, 40100, Kenya
Novartis Investigative Site
RECRUITING

Kisumu, 40100, Kenya
Novartis Investigative Site
RECRUITING

Kisumu, 54 40100, Kenya
Novartis Investigative Site
RECRUITING

Siaya, 40600, Kenya
Novartis Investigative Site
RECRUITING

Kampala, 101, Uganda
Novartis Investigative Site
RECRUITING

Masaka, Uganda
Novartis Investigative Site
RECRUITING

Tororo, 10102, Uganda
Southern Specialty Research
RECRUITING

Flowood, Mississippi, 39232, United States
Spoknwrdclinicaltrials
RECRUITING

Easton, Pennsylvania, 18045, United States
The Johns Hopkins University School of Medicine
RECRUITING

Baltimore, Maryland, 21205, United States
U of TX Health Science Ct
RECRUITING

Houston, Texas, 77030, United States
University Of Alabama
RECRUITING

Birmingham, Alabama, 35233, United States
University of Florida
RECRUITING

Jacksonville, Florida, 32209, United States
WCG Sonar Clinical Research
RECRUITING

Riverdale, Georgia, 30274, United States
Wake Forest University Baptist Medical Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.